Value
5.2/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 8.6 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 1.3 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 72.9x
- ▸PEG: 0.11
RDNT · Why this verdict
Why RadNet (RDNT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
RadNet's quality score of 2.1 out of 10 reflects near-zero return on assets of 1.1%, near-zero net margins, and a business model that generates minimal profit relative to the assets deployed — making it technically below the 4.0 minimum quality threshold despite 22% revenue growth. Quality breakdown | Quality score improves to above 3.5 within 12 months as revenue scale begins generating operating leverage and margins move meaningfully above zero. | →Stable |
| CounterHealthcare diagnostics companies often operate at thin margins due to the capital-intensive nature of imaging center operations and ongoing depreciation of equipment, making sub-4% quality scores structurally common in this sub-industry rather than a sign of business failure. | ||
RadNet is growing revenue at 22% year-over-year and shows volume accumulation (rising on-balance volume) and momentum recovery from a death cross with MACD improving — indicating the business is growing and market participants may be beginning to anticipate a quality inflection point. Momentum breakdown | Revenue growth exceeds 20% year-over-year for at least 2 consecutive quarters, and the momentum score rises above 5.5 within 12 months as price recovery continues. | →Stable |
| CounterThe 22% revenue growth partially reflects a low base from the prior period; the analyst upside of 57% is based on a price target that assumes successful execution on AI-assisted radiology initiatives that are not yet generating material revenue. | ||
RadNet has beaten earnings in 2 of the last 4 quarters but also missed in 2 — including a miss of negative 46% in the most recent quarter — with an average positive surprise of only 13.2%, indicating inconsistent execution and difficulty in managing investor expectations quarter to quarter. Earnings | RadNet beats earnings estimates in at least 3 of the next 4 quarters with consistent positive surprises above 5%, indicating execution has stabilized. | →Stable |
| CounterThe 97.9% beat in one quarter suggests that when the company does outperform expectations, the magnitude can be large — potentially driven by favorable imaging volumes or payer mix shifts — and this variability may average out to positive over time. | ||
A short interest of 14% of the float combined with analyst consensus projecting 57% upside creates a significant disconnect between institutional lenders (who are funding short positions expressing skepticism) and sell-side analysts (who are projecting strong appreciation) — a tension that will be resolved by future earnings results. Risk breakdown | Short interest falls below 10% within 12 months as either positive results drive short covering or analyst targets are cut to reflect disappointing execution. | →Stable |
| CounterThe analyst upside of 57% with 8 covering analysts — more than lightweight coverage — suggests the bull case is well-researched, and high short interest in a name with strong analyst consensus can indicate that shorts are on the wrong side of a recovery thesis. | ||
RadNet's quality score of 2.1 out of 10 reflects near-zero return on assets of 1.1%, near-zero net margins, and a business model that generates minimal profit relative to the assets deployed — making it technically below the 4.0 minimum quality threshold despite 22% revenue growth.
→StableQuality breakdown
- Expectation
- Quality score improves to above 3.5 within 12 months as revenue scale begins generating operating leverage and margins move meaningfully above zero.
CounterHealthcare diagnostics companies often operate at thin margins due to the capital-intensive nature of imaging center operations and ongoing depreciation of equipment, making sub-4% quality scores structurally common in this sub-industry rather than a sign of business failure.
RadNet is growing revenue at 22% year-over-year and shows volume accumulation (rising on-balance volume) and momentum recovery from a death cross with MACD improving — indicating the business is growing and market participants may be beginning to anticipate a quality inflection point.
→StableMomentum breakdown
- Expectation
- Revenue growth exceeds 20% year-over-year for at least 2 consecutive quarters, and the momentum score rises above 5.5 within 12 months as price recovery continues.
CounterThe 22% revenue growth partially reflects a low base from the prior period; the analyst upside of 57% is based on a price target that assumes successful execution on AI-assisted radiology initiatives that are not yet generating material revenue.
RadNet has beaten earnings in 2 of the last 4 quarters but also missed in 2 — including a miss of negative 46% in the most recent quarter — with an average positive surprise of only 13.2%, indicating inconsistent execution and difficulty in managing investor expectations quarter to quarter.
→StableEarnings
- Expectation
- RadNet beats earnings estimates in at least 3 of the next 4 quarters with consistent positive surprises above 5%, indicating execution has stabilized.
CounterThe 97.9% beat in one quarter suggests that when the company does outperform expectations, the magnitude can be large — potentially driven by favorable imaging volumes or payer mix shifts — and this variability may average out to positive over time.
A short interest of 14% of the float combined with analyst consensus projecting 57% upside creates a significant disconnect between institutional lenders (who are funding short positions expressing skepticism) and sell-side analysts (who are projecting strong appreciation) — a tension that will be resolved by future earnings results.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% within 12 months as either positive results drive short covering or analyst targets are cut to reflect disappointing execution.
CounterThe analyst upside of 57% with 8 covering analysts — more than lightweight coverage — suggests the bull case is well-researched, and high short interest in a name with strong analyst consensus can indicate that shorts are on the wrong side of a recovery thesis.
TrendMatrix Research · core thesis
Engine thesis — one sentence
RadNet operates in the healthcare diagnostics sector with 22% revenue growth and 57% analyst upside, but its quality score of 2.1 out of 10 reflects zero net margin, weak return on assets, no competitive moat, and mixed earnings execution — leaving this as a growth story that has not yet translated into business quality sufficient to meet minimum investment thresholds.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.6 |
| ROA | 1.1 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 4.5 |
| Moat | 4.9 |
| Piotroski F | 5.6 |
- ▸No competitive moat
- ▸Quality concerns
Growth
8.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 8.0 |
- ▸Strong growth: 22% YoY
Momentum
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 7.1 |
- ▸Overbought (RSI 71)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 8.6 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 31%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $2,708,360 (0.050% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.2 |
| quality rank | 4.2 |
| growth rank | 7.2 |
Technical
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.7 |
| 52w position | 6.0 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.4 |
| days to cover | 0.0 |
| volatility | 0.6 |
| put call | 10.0 |
| implied vol | 2.4 |
| beta | 5.5 |
| debt equity | 4.1 |
- ▸High IV: 65%
Catalyst
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 9.1 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.9>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.9<1.5@spot
Warning (1)
- DEATH_CROSS:momentum=7.9>=5.0 recovering
Reward-to-Risk
0.90
Upside
+13.6%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 71
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.36>1.3
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 8.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.9<1.5@spot.
The strongest dimensions are Growth at 8.0, Momentum at 7.9, and Sentiment at 7.3; the weakest are Quality at 2.1, Technical at 2.2, and Risk (lower is worse) at 3.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.90 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Floor
Trip ifNet margin remains below 0% for 3 or more consecutive quarters, confirming that scale is not generating the operating leverage required to improve business quality.
- P2Revenue Growth Momentum Recovery
Trip ifRevenue growth falls below 10% year-over-year in any quarter, indicating meaningful deceleration from the current 22% growth trajectory.
- P3Mixed Earnings Execution
Trip ifEarnings surprise falls below -30% in at least 2 of the next 4 quarters, confirming that the inconsistent execution pattern is worsening rather than stabilizing.
- P4High Short Interest Analyst Disconnect
Trip ifAnalyst consensus price target falls below $65, indicating sell-side analysts are reducing forward expectations toward current market prices and the 57% upside thesis is being abandoned.